Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
→ DOLLAR RECALL ON THE AGENDA (From Golden Crest) (Ad) Free ZBH Stock Alerts

Zimmer Biomet (ZBH) Stock Forecast & Price Target

$106.57
+0.30 (+0.28%)
(As of 07/3/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 17 Analyst Ratings

Consensus Price Target

$131.76
23.64% Upside
High Forecast$155.00
Average Forecast$131.76
Low Forecast$115.00
TypeCurrent Forecast
7/5/23 to 7/4/24		1 Month Ago
6/5/23 to 6/4/24		3 Months Ago
4/6/23 to 4/5/24		1 Year Ago
7/5/22 to 7/5/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
10 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$131.76$133.75$139.39$143.67
Forecasted Upside23.64% Upside12.04% Upside12.55% Upside10.75% Upside

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zimmer Biomet Stock vs. The Competition

TypeZimmer BiometMedical CompaniesS&P 500
Consensus Rating Score
2.29
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside23.64% Upside1,007.99% Upside12.07% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/2/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetIn-Line ➝ In-Line$130.00 ➝ $115.00+8.74%
7/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. O'brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Neutral$140.00 ➝ $115.00+5.96%
5/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetUnderweight ➝ Underweight$130.00 ➝ $125.00+9.39%
5/30/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral$129.00+12.04%
5/21/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Buy$150.00+25.89%
Re: We’re giving you all this for less than a pair of socks (Ad)

The Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4.

Don't let this unprecedented offer slip away.
5/3/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$137.00 ➝ $130.00+8.35%
5/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$150.00 ➝ $155.00+29.43%
4/3/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$134.00 ➝ $140.00+8.12%
2/23/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold ➝ Hold$130.00+0.61%
2/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$115.00 ➝ $125.00+1.90%
2/9/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$140.00+15.14%
1/3/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$133.00 ➝ $137.00+13.70%
12/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$120.00 ➝ $125.00+6.56%
11/13/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Outperform ➝ Market Outperform$160.00 ➝ $140.00+31.14%
10/20/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral$120.00+14.56%
8/28/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$139.00+20.62%
8/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$116.00 ➝ $125.00-3.84%
5/18/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
5/18/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
5/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$160.00 ➝ $165.00+22.19%
5/3/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
5/3/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$121.00 ➝ $147.00+4.13%
5/3/2023FIG Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral
5/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderperform ➝ Neutral
5/3/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$145.00 ➝ $172.00+20.27%
5/3/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$136.00 ➝ $152.00+6.29%
3/31/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderperform ➝ Hold$115.00 ➝ $130.00+2.56%
2/6/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$125.00 ➝ $140.00+8.15%
11/23/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderweight ➝ Equal Weight$116.00 ➝ $124.00+7.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:08 AM ET.

ZBH Forecast - Frequently Asked Questions

What is Zimmer Biomet's stock forecast and purchase recommendation?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $131.76, with a high forecast of $155.00 and a low forecast of $115.00. The consensus rating for Zimmer Biomet stock is Hold based on the current 1 sell rating, 10 hold ratings and 6 buy ratings for ZBH. Learn more on ZBH's analyst rating history.

Do Wall Street analysts like Zimmer Biomet more than its competitors?

Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.

Is Zimmer Biomet being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade and 1 downgrade by analysts.

Does Zimmer Biomet's stock price have much upside?

According to analysts, Zimmer Biomet's stock has a predicted upside of 12.35% based on their 12-month stock forecasts.

What analysts cover Zimmer Biomet?

Zimmer Biomet has been rated by research analysts at Argus, Barclays, Evercore ISI, Needham & Company LLC, Oppenheimer, Piper Sandler, The Goldman Sachs Group, and Truist Financial in the past 90 days.


Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:ZBH) was last updated on 7/4/2024 by MarketBeat.com Staff

From Our Partners
Operation Replace Biden is a Go
Last night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...
The Freeport Society | Sponsored
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...
Priority Gold | Sponsored
Breaking News: Elon Musk Invents New Type of A.I. (Shocking)
Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...
InvestorPlace | Sponsored
Re: We’re giving you all this for less than a pair of socks
The Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...
StockEarnings | Sponsored
25th Amendment
It's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.
Stansberry Research | Sponsored
1k a day while computer does all work?
What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...
Digital Mavericks Media | Sponsored
Urgent: Safeguard Your Finances from Biden NOW
Have you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...
Golden Crest | Sponsored
New Government Policy to Wipe Out Seniors Wealth
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...
Oasis Gold | Sponsored